Press Room

News / Oct 01, 2014

Hovione Cork – New General Manager - Paul Downing – since 1st October 2014

Paul joined Hovione on the 1st of October 2014. He holds a BSc in Chemical and Pharmaceutical Science from the University of Sunderland (UK) and a PhD in Organic Chemistry (asymmetric synthesis using organometallics) from Sheffield University (UK). He started his industrial career with Fisons Pharmaceuticals in Loughborough, where he worked in the R&D Analytical Laboratory. In early 1997, Paul joined Ciba-Geigy in Grimsby as a Process Chemist in the Chemical Operations area (Ciba-Geigy merged with Sandoz at that time and became Novartis later in 1997). He subsequently held several senior lead roles in both Quality and Production with Novartis. In 2007 he moved to New York to head up the Operations Unit  for Pharmaceutical Operations. As a result of Paul’s success in this function he was asked, in 2009, to take on the role of Global Head of Pharmaceutical Operations Strategy for Technical Operations at Head Office in Basel, where he stayed until 2012. Paul then chose to return to Cork with his family  and was invited by Chanelle Group to become Director of Operations near Galway.

Paul brings to Hovione over 20 years of relevant experience of development, quality, APIs manufacturing and formulation, as well as pharma strategy with Novartis and Chanelle. He also has considerable expertise in operational efficiency and world-class team leadership in pharma operations.

 

Hovione Cork - click here

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025